Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells by Leutenegger, Martin et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29
Intestinal Epithelial Cells
Leutenegger, Martin; Bruckner, Ramona; Spalinger, Marianne R; Lang, Silvia; Rogler, Gerhard; Scharl,
Michael
Abstract: Background Fistula formation affects up to 50ofCrohn′sdisease(CD)patientsandcausesconsiderablemorbidity.Currentpharmacologicalmanagementmainlyincludesantibiotics, immunosuppressives, andanti−
TNFantibodies.CDfistulasdevelopfromintestinalepithelialcellsundergoingepithelial−to−mesenchymaltransition(EMT ).TGF , themostimportantinducerofEMT, isdetectablearoundCDfistulatractsandinducesexpressionoftheEMT−
associatedtranscriptionfactorsSNAIL1andSLUGaswellasofIL−13.Conversely, togetherwithTNF, IL−
13inducestheexpressionofthetranscriptionfactorEts−1and6−integrin, whichareassociatedwithcellinvasiveness.EribulinisasyntheticderivativeofhalichondrinB, alargepolyethermacrolide, whichreversesEMTintriple−
negativebreastcancer(TNBC)cells.Here, weinvestigatedwhetherEribulinmightbeapotentialtherapeuticoptionforCDfistulasviatheinhibitionofEMT.SummaryChronictreatmentwithhighconcentrationsofEribulin(>
5ng/ml)istoxicforintestinalepithelialcells(IEC), andEribulintreatmentdoesnotdecreasethemRNAexpressionofEMTmarkersinHT−
29monolayersnorpreventEMTinHT−29spheroids.TogetherwithTNF,EribulininducestheexpressionofvimentinandSLUGmRNAinHT−
29spheroidsbutconcomitantlyalsopromotesE−cadherinexpression.KeyMessagesOurdatasuggestthatthepreviouslyreportedantimetastaticeffectofEribulininTNBCbyreversingEMTdoesnotapplytoIEC.Interestingly, EribulinpromotesE−
cadherinexpression, suggestinganadditionalmechanism.TheincreaseofE−cadherinmightpointtowardsthedescribedroleforEribulininreversingEMT.Takentogether, ourdatadonotsupportaroleforEribulinastreatmentoptionforCD−
associatedfistulas.
DOI: https://doi.org/10.1159/000490052
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-158473
Journal Article
Published Version
Originally published at:
Leutenegger, Martin; Bruckner, Ramona; Spalinger, Marianne R; Lang, Silvia; Rogler, Gerhard; Scharl,
Michael (2018). Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal
Epithelial Cells. Inflammatory Intestinal Diseases, 2(4):211-218.
DOI: https://doi.org/10.1159/000490052
Original Paper
Inflamm Intest Dis 2017;2:211–218
Eribulin Does Not Prevent  
Epithelial-to-Mesenchymal Transition  
in HT-29 Intestinal Epithelial Cells
Martin Leutenegger a    Ramona Bruckner a    Marianne R. Spalinger a    Silvia Lang a    
Gerhard Rogler a, b    Michael Scharl a, b    
a
 Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich,  
Zurich, Switzerland; b Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
Received: October 10, 2017
Accepted: May 10, 2018
Published online: July 10, 2018
Prof. Dr. Michael Scharl, MD
Department of Gastroenterology and Hepatology
University Hospital Zurich, Rämistrasse 100
CH–8091 Zurich (Switzerland)
E-Mail michael.scharl @ usz.ch
© 2018 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/iid
DOI: 10.1159/000490052
Keywords
Crohn’s disease · Fistulas · Eribulin ·  
Epithelial-to-mesenchymal transition
Abstract
Background: Fistula formation affects up to 50% of Crohn’s 
disease (CD) patients and causes considerable morbidity. 
Current pharmacological management mainly includes an-
tibiotics, immunosuppressives, and anti-TNF antibodies. CD 
fistulas develop from intestinal epithelial cells undergoing 
epithelial-to-mesenchymal transition (EMT). TGFβ, the most 
important inducer of EMT, is detectable around CD fistula 
tracts and induces expression of the EMT-associated tran-
scription factors SNAIL1 and SLUG as well as of IL-13. Con-
versely, together with TNF, IL-13 induces the expression of 
the transcription factor Ets-1 and β6-integrin, which are as-
sociated with cell invasiveness. Eribulin is a synthetic deriva-
tive of halichondrin B, a large polyether macrolide, which re-
verses EMT in triple-negative breast cancer (TNBC) cells. 
Here, we investigated whether Eribulin might be a potential 
therapeutic option for CD fistulas via the inhibition of EMT. 
Summary: Chronic treatment with high concentrations of 
Eribulin (> 5 ng/ml) is toxic for intestinal epithelial cells (IEC), 
and Eribulin treatment does not decrease the mRNA expres-
sion of EMT markers in HT-29 monolayers nor prevent EMT 
in HT-29 spheroids. Together with TNF, Eribulin induces the 
expression of vimentin and SLUG mRNA in HT-29 spheroids 
but concomitantly also promotes E-cadherin expression. 
Key Messages: Our data suggest that the previously report-
ed antimetastatic effect of Eribulin in TNBC by reversing EMT 
does not apply to IEC. Interestingly, Eribulin promotes E-cad-
herin expression, suggesting an additional mechanism. The 
increase of E-cadherin might point towards the described 
role for Eribulin in reversing EMT. Taken together, our data 
do not support a role for Eribulin as treatment option for CD-
associated fistulas. © 2018 S. Karger AG, Basel
Introduction
Fistulas represent a frequent and relapsing complica-
tion in Crohn’s disease (CD) and can affect up to 50% of 
the patients at least once. Most common forms occur as 
perianal, enteroenteric, enterovesical, enterouterine, or 
Leutenegger/Bruckner/Spalinger/Lang/
Rogler/Scharl
Inflamm Intest Dis 2017;2:211–218212
DOI: 10.1159/000490052
enterovaginal and often cause considerable morbidity. 
Treatment options depend on symptom severity, fistula 
location, fistula complexity, and the presence of compli-
cations. The current pharmacological management in-
cludes mainly antibiotics, immunosuppressives, and an-
ti-TNF antibodies. However, up to 30% of the perianal 
fistulas often require recurring surgical management [1], 
and therefore, the need for novel, nonsurgical treatment 
options is high.
Histomorphologically, CD fistulas consist of a central 
fissure, which is lined by granulation tissue [2]. About 
one-fourth of all CD fistulas have a central lining epithe-
lium (“epithelialized fistulas”), which consists of flattened 
epithelial cells originating from the small intestine or co-
lon without goblet cells, or of a narrow squamous epithe-
lium present in enterocutaneous or perianal fistulas. In 
“nonepithelialized fistulas,” some areas are lined with 
myofibroblast-like cells, the so-called transitional cells 
(TC), which transform into mucosal epithelial cells in the 
transitional zone. Functionally, the migratory potential of 
colonic lamina propria fibroblasts in CD patient intestine 
is reduced compared to non-IBD or ulcerative colitis pa-
tients resulting in a decreased wound healing potential 
[3]. Migration of intestinal epithelial cells (IEC), in turn, 
is induced [4].
To become mesenchymal-like myofibroblasts, IEC 
must undergo conversion in a process called epithelial-
to-mesenchymal transition (EMT). Here, the differenti-
ated epithelial cells acquire a mesenchymal phenotype 
(e.g., enhanced migratory capacity, invasiveness, elevated 
resistance to apoptosis, and increased production of ex-
tracellular matrix, components) as demonstrated by the 
loss of epithelial markers, such as E-cadherin, and the ex-
pression of mesenchymal markers, such as vimentin [5]. 
EMT is also critically involved in the formation of TC [6]. 
Further, EMT has been demonstrated to play a key role 
for the development and invasiveness of epithelial carci-
nomas, such as breast cancer, lung cancer, or colorectal 
carcinoma [7–9]. We have recently demonstrated that 
EMT plays a critical role for fistula pathogenesis [10, 11]. 
TGFβ, which is the most important inducer of EMT that 
also induces the EMT-associated transcription factors 
SNAIL1 and SLUG [12], is expressed around CD fistula 
tracts. Additionally, TGFβ induces IL-13 expression via 
β-catenin and DKK-1 [4, 13]. IL-13, together with TNF, 
then induces the expression of Ets-1 transcription factor 
and β6-integrin, which are associated with cell invasive-
ness [14]. 
Eribulin is a synthetic derivative of halichondrin B, a 
large polyether macrolide isolated from a rare marine 
Japanese sponge. It inhibits cell proliferation by binding 
tubulin and destabilizing microtubule dynamics [15, 
16]. Tubulin is sequestered into nonfunctional aggre-
gates, leading to an irreversible arrest at cell cycle phase 
G2-M and after prolonged mitotic blockade finally to 
apoptosis [17]. In contrast to other antimicrotubule 
agents, Eribulin inhibits only microtubule growth with-
out an effect on the shortening of microtubule in asso-
ciation with the sequestration of tubulin into aggregates 
[18]. Eribulin-induced apoptosis includes proteolytic 
activation of caspase-3 and caspase-9 and cleavage of 
the caspase-3-substrate poly(ADP-ribose) polymerase 
(PARP) [19].
To date, Eribulin is used as a treatment in triple-nega-
tive breast cancer (TNBC) [20]. The major part of TNBC 
have stem cell/basal-like properties [21]. Eribulin revers-
es EMT in TNBC cells. Amongst other genes, Eribulin 
treatment upregulates the expression of the epithelial 
marker E-cadherin and downregulates the expression of 
N-cadherin, vimentin, and SLUG. Eribulin modulates the 
TGFβ signaling pathway via downregulation of Smad 
phosphorylation, which results in a reduced expression of 
EMT-related genes [22, 23]. To assess a potentially thera-
peutic role for Eribulin in the treatment of CD-associated 
fistulas, we studied the effects of Eribulin on the human 
colon adenocarcinoma cells, HT-29, in different in vitro 
models.
Material and Methods
Cell Culture
Human HT-29 IEC were either grown as monolayers or spher-
oids in a humidified atmosphere with 10% CO2 at 37  ° C in low 
glucose Dulbecco’s modified Eagle medium (DMEM; Invitrogen, 
Carlsbad, CA, USA) containing 1,000 mg/L D-glucose, L-gluta-
mine, and sodium pyruvate, as described below. The medium was 
additionally supplemented with 5% fetal calf serum (FCS; VWR, 
Darmstadt, Germany).
Cell Viability Assay
HT-29 cells were seeded onto 96-well plates. After 12 h, the 
medium was replaced by low-glucose DMEM without additives. 
After 8 h, the medium was replaced by low-glucose DMEM with 
0.1, 0.5, 1, 5, 50, 100, or 500 ng/mL Eribulin as indicated and 
stimulated for 4, 8, 24, 48, and 72 h. Cell supernatant was used to 
perform an LDH assay (Sigma-Aldrich, St. Louis, Missouri, 
USA), which quantifies LDH released after cell damage. Cell 
Counting Kit-8 (CCK8; Dojindo Molecular Technologies, Rock-
ville, Maryland, USA) was used to evaluate cell proliferation and 
cytotoxicity. This assay quantifies the dehydrogenase activity in 
living cells, which is directly proportional to the number of living 
cells.
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Fig. 1. Eribulin concentrations > 5 ng/mL and a stimulation time > 
48 h induce cell death in HT-29 IEC. Optical density (OD) values 
were normalized to control (Ctrl) using the Cell Counting Kit-8 
(CCK8) assay (a, n = 2) and using the LDH assay (b, n = 2). Ratio 
of cleaved/uncleaved caspase-3 and PARP after stimulation with 
Eribulin. Eribulin causes apoptosis in HT-29 IEC cells at higher 
concentrations and stimulation time points over 24 h (c). Numbers 
correspond to Eribulin concentrations (ng/mL) and the respective 
stimulation time. Relative mRNA expression of SNAIL, SLUG, vi-
mentin, and E-cadherin after stimulation for 72 h (d–g) and 6 days 
(h–k) with Eribulin. Numbers correspond to Eribulin concentra-
tions (ng/mL). d n = 1–3. e n = 1. f n = 3. g n = 2–5. h n = 1–3. 
i n = 1–3. j n = 1–3. k n = 1–3. 
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Stimulation of HT-29 Cells
After growing HT-29 cells in 12-well plates for 24 h, the me-
dium was removed and replaced by low-glucose DMEM without 
additives. HT-29 cells were stimulated with 50 ng/mL human re-
combinant TNFα (Calbiochem/Merck, Darmstadt, Germany; 
VWR) or with 50 ng/mL human recombinant TGF-β1 (Calbio-
chem/Merck). After 24 h, the medium was replaced with low-glu-
cose DMEM containing 0.1, 0.5, 1, 5, 50, 100, or 500 ng/mL Eribu-
lin for 72 h or 6 days, as indicated. TGFβ was only added to cells 
stimulated for 72 h. Chemically synthesized Eribulin mesylate was 
obtained from Eisai Co., Ltd (Tsukuba, Japan).
Spheroids as in vitro Model for EMT
As an in vitro model for EMT, HT-29 cells were grown as 
spheroids [14]. 4.5 × 103 cells per spheroid were resuspended in 24 
μL of HT-29 medium, seeded in Terasaki plates (Greiner-Mi-
crotest Plates, TC; EBIS/Huber & Co) with 60 cavities and grown 
for 7 days. After 7 days, spheroids were stimulated with either 1 μL 
of HT-29 medium without additives, 50 ng/mL of TNFα, as well as 
with 0.1, 0.5, 1, 5, 50, and 200 ng/mL Eribulin. Spheroids were har-
vested after 7 days.
Western Blotting
An aliquot of each lysate was mixed with NuPAGE 4 × LSD 
sample buffer (Invitrogen) and 50 mM dithiothreitol (Sigma) and 
boiled for 5 min at 98  ° C. Proteins were separated by SDS-poly-
acrylamide gel electrophoresis and transferred onto nitrocellulose 
membranes (Invitrogen). Membranes were blocked with 3% 
blocking solution and rabbit anti-PARP or rabbit anti-CASP3 an-
tibody (1: 1,000 in 3% blocking solution; Abcam, Cambridge, UK) 
was applied overnight. The membranes were washed with Tris 
buffered saline containing 1% Tween 20 (1% TBST). HRP-labelled 
secondary anti-rabbit-IgG-antibody (1: 4,000 in 3% blocking solu-
tion; Santa Cruz Biotechnology, Dallas, TX, USA) was added for 
90 min, and the membranes were washed for 1 h with 1% TBST. 
Finally, immunoreactive proteins were detected using an en-
hanced chemoluminescence detection kit (GE Healthcare, Little 
Chalfont, UK).
Real-Time Polymerase Chain Reaction
Cell lysis was performed using RLT-buffer (Quiagen, Valencia, 
CA, USA) containing DTT. RNA was isolated using RNeasy Plus 
Mini Kit (Quiagen) according to the manufacturer’s instructions. 
The RNA concentration was subsequently determined by absor-
bance at 230 nm using NanoDrop ND1000 (Thermo Scientific, 
Waltham, MA, USA). Complementary DNA synthesis was per-
formed using a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA). TaqMan Assays and 
TaqMan Gene Expression Master Mix were obtained from Ap-
plied Biosystems. Real-time polymerase chain reaction was per-
formed in a 7900HT Fast TR-PCR System using SDS 2.2 software 
(Applied Biosystems). Conditions were set on 45 cycles, denatur-
ation of 1 s at 95  ° C, and the annealing/extending at 60  ° C for 20 s. 
Triplicate measurements were performed. Results were analyzed 
with the ∆∆CT method. The measured values were normalized to 
endogenously expressed β-actin.
Statistical Analysis
Data are shown as mean +/– S.E.M. for a series of n experi-
ments. Statistical analyses were performed (GraphPad Software, 
Inc., San Diego, CA, USA) by one-way analysis of variance fol-
lowed by Dunnetts’s multiple comparison post hoc test. p < 0.05 
was considered significant.
Results
Eribulin Is Toxic for Intestinal Epithelial Cells
Our first aim was to define non-cell-toxic concentra-
tions of Eribulin, since the desired therapeutic effect in 
patients with CD fistulas would be to reverse or prevent 
the process of EMT in contrast to the desired cytotoxic 
effect in patients suffering from TNBC. First, we deter-
mined the effects of Eribulin on the viability of HT-29 
IEC using a CCK-8 assay. We found that the treatment of 
HT-29 IEC for up to 24 h with Eribulin in a concentration 
range from 0.1–500 ng/mL did not affect cell viability. 
However, incubation times of 48 or 72 h at Eribulin con-
centrations of 5 ng/mL and higher reduced cell viability 
(Fig. 1a). An LDH release assay as a marker for cell death 
showed similar results (Fig. 1b). At Eribulin concentra-
tions of ≥5 ng/mL, the cells peeled off the wells, further 
confirming the toxic effect. This led us to use concentra-
tions < 5 ng/mL for further experiments, since at lower 
concentrations, less Eribulin-induced cytotoxicity was 
detected. 
We next studied molecular markers for apoptosis in 
HT-29 IEC. We detected increased cleavage of caspase-3 
Fig. 2. After 7 days, Eribulin induces mRNA expression of vimen-
tin and SNAIL but at the same time increases E-cadherin mRNA 
levels in HT-29 cells grown as spheroids. mRNA expression of 
SLUG (a), SNAIL (b), E-cadherin (c), and vimentin (d). Together, 
Eribulin and TNFα induce an even higher vimentin and SLUG 
mRNA expression, while at the same time they also increase E-
cadherin expression levels and leave SNAIL expression unaltered 
in HT-29 spheroids after 7 days. mRNA expression of SLUG (e), 
SNAIL (f), E-cadherin (g), and vimentin (h). Eribulin reduces the 
size of HT-29 spheroids at higher concentrations after 7 days of 
stimulation but does not induce EMT (i). TNFα treatment induces 
a fringed edge in the HT-29 spheroids, suggesting the onset of 
EMT. Co-treatment of Eribulin with TNFα reduces the size of the 
spheroids at increasing Eribulin concentrations (j). Numbers cor-
respond to Eribulin concentrations (ng/mL). Three independent 
experiments were performed for all assays. Asterisks indicate 
significant differences versus the respective control. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
(For figure see next page.)
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and PARP after treatment with Eribulin for 48 h at a con-
centration of 5 ng/mL (Fig. 1c). Lower concentrations of 
Eribulin did not promote cleavage of caspase-3 or PARP 
in our cell model. Interestingly, Eribulin had no cell toxic 
effect upon shorter treatment intervals regardless of the 
concentration. We therefore concluded that Eribulin 
concentrations of max. 5 ng/mL were reasonable for fur-
ther experiments.
Eribulin Does Not Affect EMT Marker Expression in 
HT-29 Monolayers
We then studied whether Eribulin would be able to af-
fect mRNA expression levels of various EMT markers in 
HT-29 IEC monolayers. To address this aim, Eribulin-
treated HT-29 cells were analyzed for the mRNA expres-
sion levels of the EMT-associated transcription factors 
SNAIL and SLUG, of the epithelial marker E-cadherin, 
and of the mesenchymal marker vimentin.
After stimulation for 72 h, treatment with Eribulin had 
no significant effect on E-cadherin mRNA expression 
levels, while SNAIL1, SLUG, and vimentin at least showed 
a minor trend for an increased expression (Fig. 1d–g). Of 
note, Eribulin did not affect TGFβ-induced effects at 
72 h treatment.
After stimulation of HT-29 IEC monolayers with Er-
ibulin for 6 days, SNAIL, SLUG, and vimentin mRNA 
expression levels were increased in a dose-dependent 
manner, SLUG and vimentin mRNA expression levels 
were decreased at higher Eribulin concentrations. How-
ever, E-cadherin levels were not significantly altered but 
showed a trend towards reduced levels at higher Eribulin 
doses (Fig. 1h–k).
Previous studies showed that Eribulin reverses EMT in 
TNBC cells [22], while our results suggest that in IEC, 
Eribulin rather increased the expression of EMT-associ-
ated molecules and mesenchymal markers in HT-29 cell 
monolayers. N-cadherin expression was also analyzed 
but was only expressed at very low levels, and no relative 
expression could be calculated.
Eribulin Does Not Prevent EMT in HT-29 Spheroids
We next studied the effects of Eribulin in our well-es-
tablished EMT cell model using HT-29 spheroids. In con-
trast to monolayers, spheroids allow to study the effect on 
tight-junction integrity and cell proliferation in a more 
physiological manner. HT-29 cells were seeded as spher-
oids and treated after 7 days with Eribulin for additional 
7 days. Eribulin did not significantly alter the expression 
levels of mRNA for the EMT marker gene SLUG and β6-
integrin. At higher concentrations, Eribulin treatment 
even enhanced mRNA expression of the mesenchymal 
markers vimentin, SLUG, and SNAIL but also of the epi-
thelial marker E-cadherin. None of the mRNA expression 
for the EMT markers was reduced (Fig.  2a–d). Micro-
scopically, the spheroids appeared smaller, but confined 
by a thin border, with increasing concentrations of Eribu-
lin (Fig. 2i). 
We then induced EMT in our HT-29 spheroids by 
stimulating with TNFα at a concentration of 50 ng/mL for 
7 days, since it has been shown that TNFα induces the 
expression of factors associated with EMT [14]. HT-29 
cells were seeded as spheroids and stimulated with Eribu-
lin and TNFα. TNFα-treatment induced the mRNA ex-
pression of the EMT marker SLUG and vimentin, clearly 
indicating the onset of EMT after 7 days. However, TNFα-
induced effects were not diminished by co-treatment 
with Eribulin, and high doses of Eribulin even enhanced 
TNFα-induced expression of SLUG and vimentin, while 
leaving SNAIL expression unaltered. (Fig. 2e–h). Inter-
estingly, E-cadherin mRNA expression was also increased 
after Eribulin co-treatment, while it was not influenced 
by TNFα-treatment alone (Fig. 2g). β6-integrin mRNA 
levels were unaltered by Eribulin and TNFα-treatment ei-
ther alone or in combination (data not shown). Micro-
scopically, spheroids revealed a rather fringed boarder af-
ter stimulation with TNFα, suggesting the onset of EMT 
(Fig. 2j). Eribulin and TNFα cotreatment reduced the size 
of the spheroids with increasing Eribulin concentrations. 
N-cadherin expression was also analyzed but was only 
expressed at very low levels, and no relative expression 
could be calculated.
Discussion
EMT has been shown to play a pivotal role for the de-
velopment of CD-associated intestinal fistulas. Eribulin is 
used in the treatment of TNBC and reverses the onset of 
EMT. Here, we investigated whether Eribulin might be 
able to affect EMT in IEC, which might provide the ratio-
nale for the use of Eribulin in the treatment of CD-asso-
ciated fistulas.
In the present study, we have demonstrated that Er-
ibulin has cytotoxic effects on HT-29 cells in high doses 
and upon prolonged treatment duration, but in low con-
centrations up to 5 ng/mL, Eribulin is not cytotoxic for 
IEC and might be suitable for targeting EMT in IEC. 
However, when grown as monolayers, Eribulin was not 
able to reverse induced EMT in HT-29 cells. This is con-
trary to previous studies, showing that Eribulin reverses 
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EMT in TNBC cells [22]. In our hands, Eribulin even in-
creases the expression of EMT markers in IEC. Interest-
ingly, in our HT-29 spheroid model, a well-established 
cell model for EMT, we found that Eribulin and TNFα 
have synergistic effects on the expression of mesenchy-
mal markers or EMT-associated genes. A plausible expla-
nation might be the loosening of cell-cell contacts because 
of EMT and subsequently an enlarged contact surface 
with Eribulin. Higher concentrations of Eribulin were 
needed to see effects on gene regulation in spheroids, as 
compared to HT-29 monolayers, probably because of 
tighter cell-cell contacts and a more epithelial-like pheno-
type of the spheroids. In conclusion, our data have shown 
that Eribulin does not reverse EMT in HT-29 IEC. 
In summary, the data from this study suggest that the 
previously reported antimetastatic effect of Eribulin in 
TNBC, by reversing EMT, does most likely not apply to 
intestinal epithelial cells. A reason for this result might be 
that HT-29 IEC already have a distinct epithelial pheno-
type more similar to a physiologically configured epithe-
lium, while TNBC seems to have a more stem-cell like 
mesenchymal behavior corresponding to the cells of an 
aggressively metastatic type of cancer. It has already been 
shown that the expression of some EMT marker genes 
predicts Eribulin sensitivity in some cell lines [24]. Inter-
estingly, Eribulin not only enhanced the mRNA expres-
sion of the EMT markers SLUG and vimentin but also 
promoted E-cadherin expression, a marker associated 
with an epithelial phenotype. This suggests that in IEC, 
Eribulin also induces other mechanisms than the already 
described ones involving EMT. Eribulin affects gene ex-
pression in different ways, holding a balance. On the one 
hand, there is the specific effect on microtubule structure 
and therefore internal cell transport mechanisms proba-
bly altering E-cadherin expression. On the other hand, 
there is the cytotoxic and proapoptotic effect causing in-
flammatory responses and probably altering SLUG ex-
pression. The increase of E-cadherin might point towards 
the also described role for Eribulin in reversing EMT. The 
low N-cadherin mRNA expressions could also be partial-
ly explained by the distinct epithelial phenotype of the 
HT-29 cells. All in all, our data suggest that Eribulin is 
likely not an appropriate therapeutic option for the treat-
ment of CD-associated fistulas.
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